-
Arsenal suffer title 'punch' by Bournemouth, Everton hold Brentford
-
Drean double breaks Glasgow hearts as Toulon reach Champions Cup semis
-
Teen star Seixas seals Basque Tour triumph, August wins sixth stage
-
Scores arrested at pro-Palestinian rally in London
-
I Am Maximus emulates Red Rum to regain Grand National crown
-
Leverkusen sink Dortmund to bring Bayern closer to title
-
Planes fly from Beirut airport despite Israeli bombing
-
Pogacar dreaming of Monument clean-sweep
-
Arteta urges Arsenal to stand up after 'punch in the face'
-
Iyer leads Punjab's chase of 220 to down Hyderabad
-
Arsenal defeat blows Premier League title race wide open
-
Buffets, baristas, but no briefings: journalists frozen out of Iran talks
-
McIlroy's Masterpiece remains the buzz at Augusta
-
Sinner brushes past Zverev to reach Monte Carlo final
-
Arsenal suffer major blow in Premier League title charge
-
UK puts Chagos handover deal in 'deep freeze' after Trump criticism
-
In Europe first, Netherlands to allow Teslas to self-drive
-
Sabrina Carpenter transforms Coachella into her own 'Sabrinawood'
-
Iran, Lebanon bore brunt of missiles and drones launched during war
-
Iran envoys meet Pakistani PM ahead of US talks
-
UK to shelve Chagos handover after Trump criticism
-
Somalia president congratulates World Cup-bound referee Omar Artan
-
Vance in Islamabad for Iran talks overshadowed by mutual mistrust
-
After Artemis II, NASA looks to SpaceX, Blue Origin for Moon landings
-
Benin leans into painful past to attract tourists
-
Britain storm into Billie Jean King Cup finals with Australia thumping
-
Russia and Ukraine set to begin Easter truce
-
Hawks clinch NBA playoff berth with win over Cavs
-
Trump administration reveals plans for massive Washington arch
-
Carney poised to win Canada majority but affordability pressure looms
-
Artemis II lunar mission draws flood of conspiracy theories
-
Extra time at Augusta helps McIlroy make Masters magic
-
Panic buttons, undercover cops: How Peru bus drivers try to stay safe
-
Iran, US to hold peace talks overshadowed by mutual mistrust
-
Artemis II astronauts return to Earth, capping historic Moon mission
-
Small US farm copes with fuel hikes from Mideast war
-
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
-
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX)
-
McIlroy seizes 36-hole record six-shot Masters lead with epic finish
-
Iranian delegation in Pakistan for talks with US, Vance en route
-
Rory McIlroy seizes Masters record six-stroke lead after 36 holes
-
Djibouti leader claims sixth straight term
-
Trump vows to boost Hungary economy if Orban wins vote
-
Mythos AI alarm bells: Fair warning or marketing hype?
-
De Zerbi 'not surprised' by backlash from Spurs fans over Greenwood
-
Marseille boost hopes of Champions League return, Monaco suffer heavy defeat
-
Frustrated Scheffler finds water hazards at Masters
-
Swing and miss: Ichiro statue reveal goes awry as bat snaps
-
China's Li flushes toilet trouble at Masters
-
Stocks up, oil down over week on guarded optimism for Iran
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.
"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."
NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.
More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com
About ZeptoMetrix®
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355
Contact Information
Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417
SOURCE: ZeptoMetrix
View the original press release on ACCESS Newswire
W.Stewart--AT